Showing results (341-350 of 8,779) with videos related to

Sort By:
Pageof 878
Pediatric Blood & Cancer|September 11, 2010
Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastomaAlekist Quach, Lingyun Ji, Vikash Mishra, et al.
Pediatric Blood & Cancer|September 11, 2010
Increasing prevalence of nasal and rectal colonization with methicillin-resistant Staphylococcus aureus in children with cancerAshok Srinivasan, Steven E Seifried, Liang Zhu, et al.
Pediatric Blood & Cancer|December 16, 2010
Bone mineral density in newly diagnosed children with neuroblastomaYoussef A Al-Tonbary, Magdy A El-Ziny, Ashraf A Elsharkawy, et al.
Pediatric Blood & Cancer|December 16, 2010
Posterior fossa syndrome after posterior fossa surgery in children with brain tumorsSerhan Küpeli, Bilgehan Yalçın, Burçak Bilginer, et al.
Pediatric Blood & Cancer|December 16, 2010
Treatment and survival patterns for germ cell tumors among 13- to 24-year olds in Yorkshire, UKRichard G Feltbower, Catherine Siller, Emma Woodward, et al.
Pediatric Blood & Cancer|May 21, 2010
Imatinib mesylate in children and adolescents with cancerRonald D Barr
Pediatric Blood & Cancer|May 21, 2010
Intensive multimodality therapy for patients with stage 4a metastatic retinoblastomaIra J Dunkel, Yasmin Khakoo, Nancy A Kernan, et al.
Pediatric Blood & Cancer|May 21, 2010
R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenograftsE Anders Kolb, Davida Kamara, Wendong Zhang, et al.
Pediatric Blood & Cancer|May 21, 2010
Infant leukemia and congenital abnormalities: a Children's Oncology Group studyKimberly J Johnson, Michelle A Roesler, Amy M Linabery, et al.
Pediatric Blood & Cancer|May 21, 2010
Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium studyStacey L Berg, Naomi Winick, Ashish Mark Ingle, et al.
Pageof 878